Nakashima H, Hirata Y, Uchihashi M, Tomita M, Fujita T
Acta Endocrinol (Copenh). 1985 May;109(1):7-12. doi: 10.1530/acta.0.1090007.
Release of immunoreactive ACTH and beta-endorphin (beta-EP) in response to corticotrophin-releasing factor (CRF) and dopaminergic agents was studied in vivo and in vitro in a patient with Cushing's disease. Iv administration of synthetic ovine (o) CRF significantly stimulated plasma ACTH release, accompanied by increase of plasma cortisol levels. Oral administration of bromocriptine significantly suppressed plasma cortisol levels. Although reduced responses of plasma ACTH and cortisol to o-CRF was observed 1 month after removal of the pituitary adenoma, these normalized 6 months after operation. In vitro perifusion of the pituitary adenoma obtained by surgery revealed that o-CRF also stimulated ACTH and beta-EP release in a dose-responsive manner (10(-9)M 10(-5)M) and that dopamine suppressed their basal secretion. Gel exclusion chromatography of the perfusates showed that the predominant component of ACTH and beta-EP before and after o-CRF stimulation coeluted with standard ACTH and beta-EP, respectively. The present data suggest that o-CRF is a potent secretagogue for ACTH and beta-EP release from the human pituitary adenoma causing Cushing's disease and that ACTH secretion from certain adenomas, possibly originating from the intermediate lobe of the pituitary gland, is partly regulated by a dopaminergic mechanism.
我们在一名库欣病患者体内和体外研究了促肾上腺皮质激素释放因子(CRF)和多巴胺能药物刺激下免疫反应性促肾上腺皮质激素(ACTH)和β-内啡肽(β-EP)的释放情况。静脉注射合成羊(o)CRF可显著刺激血浆ACTH释放,并伴有血浆皮质醇水平升高。口服溴隐亭可显著抑制血浆皮质醇水平。虽然垂体腺瘤切除术后1个月观察到血浆ACTH和皮质醇对o-CRF的反应减弱,但术后6个月这些反应恢复正常。对手术切除的垂体腺瘤进行体外灌流实验发现,o-CRF也能以剂量依赖方式(10^(-9)M至10^(-5)M)刺激ACTH和β-EP释放,多巴胺可抑制它们的基础分泌。对灌流液进行凝胶排阻色谱分析表明,o-CRF刺激前后,ACTH和β-EP的主要成分分别与标准ACTH和β-EP共洗脱。目前的数据表明,o-CRF是引起库欣病的人垂体腺瘤释放ACTH和β-EP的有效促分泌剂,某些腺瘤(可能起源于垂体中间叶)的ACTH分泌部分受多巴胺能机制调节。